EUVIMEDEUVIMED entdecken
Open Access

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort

Bianza Tinotenda Mbavha, Roslyn Stella Thelingwani iD, Zedias Chikwambi, Anna Mary Nyakabau, Collen Masimirembwa, the Consortium for Genomics and Therapeutics in Africa

British Journal of Clinical Pharmacology · 2023-10 · 89 (10) · 3209-3216

DOI: 10.1111/bcp.15827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 26.06.2023. Verfasst von Bianza Tinotenda Mbavha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, African Institute of Biomedical Science and Technology (AiBST), Beatrice, Zimbabwe. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, European and Developing Countries Clinical Trials Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamoxifen is the most used hormonal therapy for oestrogen receptor‐positive breast cancer. CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations in endoxifen plasma concentrations are associated with CYP2D6 polymorphisms. This study aimed to determine the association between the CYP2D6 polymorphisms and endoxifen plasma concentrations in a cohort of Zimbabwean breast cancer patients ( n = 40). TaqMan genotyping and copy number assays were done to determine CYP2D6 genotypes. Tamoxifen and metabolites were quantitated using LC‐MS/MS. The population had high frequencies of the CYP2D6 reduced function alleles, *17 (15%) and *29 (18%). The median endoxifen concentration was 4.78 ng/mL, and in 55% of the patients, mostly intermediate metabolizers were below the endoxifen therapeutic threshold of 5.97 ng/mL. The CYP2D6 phenotypes and activity scores were significantly associated with endoxifen plasma concentrations ( P = 0.0151) and with endoxifen to N‐desmethyl‐tamoxifen ratios ( P = 0.0006).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemalePharmacogeneticsCytochrome P-450 CYP2D6Chromatography, LiquidZimbabweAntineoplastic Agents, HormonalTandem Mass SpectrometryTamoxifenGenotype

Stichwörter der Autor:innen

CYP2D6breast cancerpharmacogeneticspharmacokineticstamoxifen

Substanzen

4-hydroxy-N-desmethyltamoxifenCytochrome P-450 CYP2D6Antineoplastic Agents, HormonalTamoxifen

Autor:innen und Institutionen

  • Department of Genomic Medicine, African Institute of Biomedical Science and Technology (AiBST), Beatrice, Zimbabwe.
  • Department of Biotechnology, Chinhoyi University of Technology, Chinhoyi, Zimbabwe.
  • Parirenyatwa Hospital Radiotherapy and Oncology Center, Harare, Zimbabwe.
  • Sydney Brenner Institute for Molecular Bioscience (SBIMB), University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Roslyn Stella Thelingwani

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • European and Developing Countries Clinical Trials Partnership
  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Mbavha, B. T., Thelingwani, R. S., Chikwambi, Z., Nyakabau, A. M., Masimirembwa, C., & the Consortium for Genomics and Therapeutics in Africa (2023). Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British Journal of Clinical Pharmacology, 89(10), 3209-3216. https://doi.org/10.1111/bcp.15827

Vancouver

Mbavha BT, Thelingwani RS, Chikwambi Z, Nyakabau AM, Masimirembwa C, the Consortium for Genomics and Therapeutics in Africa. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British Journal of Clinical Pharmacology. 2023;89(10):3209-3216. doi:10.1111/bcp.15827

BibTeX
@article{Mbavha2023,
  author = {Mbavha, Bianza Tinotenda and Thelingwani, Roslyn Stella and Chikwambi, Zedias and Nyakabau, Anna Mary and Masimirembwa, Collen and the Consortium for Genomics and Therapeutics in Africa, the Consortium for Genomics and Therapeutics in Africa},
  title = {Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {10},
  pages = {3209--3216},
  doi = {10.1111/bcp.15827}
}
Kostenlos starten →